Skip to main content
Top
Published in: Clinical Rheumatology 3/2016

01-03-2016 | Case Based Review

Pulmonary Langerhans Histiocytosis: an uncommon cause of interstitial pneumonia in a patient with Sjögren syndrome

Authors: Andrés González García, José Luis Callejas Rubio, Raquel Ríos Fernández, Norberto Ortego Centeno

Published in: Clinical Rheumatology | Issue 3/2016

Login to get access

Abstract

Sjögren syndrome is a chronic, systemic, and autoimmune disorder that targets exocrine glands by remarkable B cell hyperactivity. Eventually, it is associated with extra-glandular clinical manifestations that affect essentially any organ system, including pulmonary involvement. Interstitial lung disease is one of the most serious pulmonary complications, and the early diagnosis is essential to initiate a prompt therapy. On the other hand, Sjögren syndrome could present concomitantly with several rheumatologic diseases such as systemic lupus erythematosus or rheumatoid arthritis. Pulmonary Langerhans Histiocytosis is a rare clonal proliferative disease characterized by pulmonary involvement by cells phenotypically similar to Langerhans cells. We describe the case of a nonsmoker 62-year-old woman with Sjögren syndrome who presented concomitantly a Pulmonary Langerhans Histiocytosis mimicking a pulmonary complication of its Sjögren. Fortunately, she had a well response to corticosteroids and azathioprine regimen. The aim of the paper is to emphasize the importance of the good differential diagnosis related to the pulmonary involvement. To the best of our knowledge, this is the first description of these two entities in the literature.
Literature
4.
go back to reference Schonfeld N, Frank W, Wenig S, Uhrmeister P, Allica E, Preussler H, Grassot A, Loddenkemper R (1993) Clinical and radiologic features, lung function and therapeutic results in pulmonary histiocytosis X. Respiration 60(1):38–44CrossRefPubMed Schonfeld N, Frank W, Wenig S, Uhrmeister P, Allica E, Preussler H, Grassot A, Loddenkemper R (1993) Clinical and radiologic features, lung function and therapeutic results in pulmonary histiocytosis X. Respiration 60(1):38–44CrossRefPubMed
5.
go back to reference Watanabe M, Naniwa T, Hara M, Arakawa T, Maeda T (2010) Pulmonary manifestations in Sjogren’s syndrome: correlation analysis between chest computed tomographic findings and clinical subsets with poor prognosis in 80 patients. JRheumatol 37(2):365–373. doi:10.3899/jrheum.090507 CrossRef Watanabe M, Naniwa T, Hara M, Arakawa T, Maeda T (2010) Pulmonary manifestations in Sjogren’s syndrome: correlation analysis between chest computed tomographic findings and clinical subsets with poor prognosis in 80 patients. JRheumatol 37(2):365–373. doi:10.​3899/​jrheum.​090507 CrossRef
6.
go back to reference Koyama M, Johkoh T, Honda O, Mihara N, Kozuka T, Tomiyama N, Hamada S, Nakamura H (2001) Pulmonary involvement in primary Sjogren’s syndrome: spectrum of pulmonary abnormalities and computed tomography findings in 60 patients. J Thorac Imaging 16(4):290–296CrossRefPubMed Koyama M, Johkoh T, Honda O, Mihara N, Kozuka T, Tomiyama N, Hamada S, Nakamura H (2001) Pulmonary involvement in primary Sjogren’s syndrome: spectrum of pulmonary abnormalities and computed tomography findings in 60 patients. J Thorac Imaging 16(4):290–296CrossRefPubMed
8.
go back to reference Auerswald U, Barth J, Magnussen H (1991) Value of CD-1-positive cells in bronchoalveolar lavage fluid for the diagnosis of pulmonary histiocytosis X. Lung 169(6):305–309CrossRefPubMed Auerswald U, Barth J, Magnussen H (1991) Value of CD-1-positive cells in bronchoalveolar lavage fluid for the diagnosis of pulmonary histiocytosis X. Lung 169(6):305–309CrossRefPubMed
10.
go back to reference Castillo D, Martin-Arroyo I, Moreno A, Balcells E, Villar A, Vicens-Zygmunt V, Vendrell M, Belda S, Portillo K, Kettou D, Aparicio F, Molina-Molina M, en nombre del grupo C (2014) Adult pulmonary Langerhans’ cell histiocytosis: approach to the reality of the Spanish population. Med Clin 143(10):433–439. doi:10.1016/j.medcli.2013.11.039 CrossRef Castillo D, Martin-Arroyo I, Moreno A, Balcells E, Villar A, Vicens-Zygmunt V, Vendrell M, Belda S, Portillo K, Kettou D, Aparicio F, Molina-Molina M, en nombre del grupo C (2014) Adult pulmonary Langerhans’ cell histiocytosis: approach to the reality of the Spanish population. Med Clin 143(10):433–439. doi:10.​1016/​j.​medcli.​2013.​11.​039 CrossRef
11.
go back to reference Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962–3970. doi:10.1002/art.22204 CrossRefPubMed Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962–3970. doi:10.​1002/​art.​22204 CrossRefPubMed
Metadata
Title
Pulmonary Langerhans Histiocytosis: an uncommon cause of interstitial pneumonia in a patient with Sjögren syndrome
Authors
Andrés González García
José Luis Callejas Rubio
Raquel Ríos Fernández
Norberto Ortego Centeno
Publication date
01-03-2016
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 3/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-015-2924-z

Other articles of this Issue 3/2016

Clinical Rheumatology 3/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.